PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Co. develops, manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). BPH is a common prostate disease. The AquaBeam Robotic System employs a single-use disposable handpiece to deliver Co.'s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted removal of prostate tissue. The PRCT stock yearly return is shown above.
The yearly return on the PRCT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRCT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|